Gene testing is the technology to detect DNA/RNA in the samples including human blood and other body fluids, and human tissues. There are two major applications. One is for the diagnosis of diseases including the detection of pathogenic microorganisms and genetic mutations that cause diseases. The other application is for disease prevention. Testing the genotype of an individual or the genotype of certain infectious agent, the disease risk of a person can be assessed, and measures can be taken to prevent or delay the possible illness.

Gene testing is one of the key sectors in IVD industry and is observing strong growth in recent years. Genetel, a wholly-owned subsidiary of Mingyuan Medicare,is the first to develop a SFDA-approved product to detect 13 different subtypes of high-risk HPV which cause the majority of cervical cancer. Genetel has also successfully developed the technology for the genotyping of each individual HPV subtypes including a SFDA approved product for the genotyping of 29 HPV subtypes. The products have the advantages of high sensitivity and specificity, fast, high throughput, and being affordable, and are suitable for the screening and diagnosis of cervical illnesses including cervical cancer. The WHO and the Chinese government are well aware of the importance of early screening and diagnosis of HPV detection in the prevention of cervical cancer, and is actively promoting the efforts for prevention of cervical cancer and the protection of women health. As people gradually realize the great benefit of gene testing including the key role of HPV testing in the prevention of cervical cancer, the demand for gene testing products will grow even faster, and the Company is confident its gene testing business will achieve fast and sustainable growth.